We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
You must tell DVLA if you have hypoglycaemia - download the correct form to let them know
Advice for medical professionals to follow when assessing drivers with diabetes mellitus.
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
The product information for all Glucagon-Like Peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists has been further updated to highlight the potential risk of severe acute pancreatitis with these products, including rare reports of necrotising and...
Experiences from a self-monitoring of blood glucose (SMBG) program in western Kenya
Updated product information for healthcare professionals and patients regarding the small risk of severe acute pancreatitis in patients taking GLP-1s.
Letter templates to GPs to confirm a child's diagnosis for an inherited metabolic disease.
Analysis of risk factors for pre-diabetes (also called non-diabetic hyperglycaemia, or NDH) and undiagnosed type 2 diabetes among adults.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).